Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) in Malawian Children
NCT03299426Phase 3Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Feb 2018
- Primary completion
- Jan 2025
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Vi-Typhoid Conjugate Vaccine in typhoid fever (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Efficacy of Vi-TCV at 36 months. Started Feb 2018; status: active, not recruiting.
02
Drugs
Vi-Typhoid Conjugate Vaccine
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT03299426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299426.